Abstract Objectives: Cognitive control is an adaptive action in a constantly changing environment required the ability to maintain intentions and goals over time and to flexibly switch between these goals in response to significant changes. This study aimed to identify the differences and the profiles of cognitive control deficits and possible candidates as endophenotypes of schizophrenia and bipolar I disorder. Methods: Five groups were included in this study: remitted patients with schizophrenia(n=42), patients in euthymic states of bipolar I disorder(n=37), unaffected first-degree relatives of probands with schizophrenia(n=35), those with bipolar I disorder(n=29), and healthy controls(n=38) who were matched on age, sex, years of education. A version of the AX-CPT paradigm was used to examine cognitive control. Psychopathology, intelligence, and psychomotor speed were also assessed. Results: Both patient groups performed worse in BX trial than the other groups(p<0.01). Patients with schizophrenia also showed higher mean error rates in AX trial(p<0.01), and delayed response in all CPT trials than the rest(p<0.01). However, firstdegree relatives of both probands did not showed deficits for the accuracy and response time in all trials. Conclusion: These findings suggest that cognitive control is impaired in schizophrenia and bipolar I disorder with poorer ability of schizophrenia, and the impairments in cognitive control seems less likely to be a possible endophenotype shared both mental disorders.
seek to identify significant genes or factors for prediction, this study proposes a data mining algorithm that integrates multiple genes and baseline profiles simultaneously, resulting in a mechanism to directly identify individuals who will response to a specific type of antipsychotic medication. Methods: The approach included revision of Latent Group Effectiveness Modeling (LGEM).
1 The revised algorithm was applied to the data obtained from the CATIE 2 study. The predictors were either (1) 13 single-nucleotide polymorphisms (SNPs) and 53 baseline variables or (2) 25 SNPs and the same 53 baseline variables, depending on the previous GWAS findings and data availability. The outcome variables were either (1) improvement in the Positive and Negative Syndrome Scale (PANSS) (Yes/No) or (2) completion of phase 1/1A (Yes/No). Each of those four predictor-outcome combinations was tried for each of the five antipsychotic drugs (Perphenazine, Olanzapine, Quetiapine, Risperidone, and Ziprasidone), leading to 20 prediction scenarios in total. Results: For 18 out of 20 prediction scenarios, all three performance measures were greater than .50 (sensitivity .51−.79, specificity .52−.79, accuracy .52−.74). Notably among several relevant predictions, the model provided a promising prediction for Ziprasidone for the case involving completion of phase 1/1A (Yes/No) predicted by 13 SNPs and 53 baseline variables (sensitivity .75, specificity .74, accuracy .74).
Conclusion:
The proposed algorithm simultaneously used both genetic information and baseline profiles to identify which individual person will benefit from a specific antipsychotic drug among the patients with schizophrenia. As this method employs a general algorithm applicable to a variety of diseases and medications, it can be easily adopted in many other clinical practices for personalized medicine.
